Wissen

Pharma Cold Chain Logistics Best Practices 2025 Führung

Pharma Cold Chain Logistics Best Practices 2025 Führung

Aktualisiert im November 26 2025

Pharma cold chain logistics best practices protect lifesaving medicines and vaccines from temperature fluctuations that can ruin their potency. In 2025 the global cold chain logistics market is booming—forecast to surge from about UNS $324.85 Milliarden in 2024 Zu UNS $862.33 Milliarden von 2032—because biologics, advanced therapies and obesity treatments depend on controlled temperatures. Noch bis zu 20 % of temperaturesensitive drugs are compromised in transit and nearly 50 % von Impfstoffen are wasted due to poor cold chain management. If you handle pharmaceuticals, you need a robust cold chain strategy that ensures products remain within their required ranges (often 2–8 °C), complies with regulations like GDP/GMP and the Gesetz zur Sicherheit der Arzneimittellieferkette (DSCSA), and leverages emerging technologies such as IoT sensors, AI analytics and blockchain for realtime visibility. This guide answers your questions and provides pharma cold chain logistics best practices to help you safeguard medicines, reduce waste and stay compliant in 2025.

1

Why are pharma cold chain logistics best practices essential? – We explain the stakes for patient safety and financial integrity, and why 2–8 °C matters for most vaccines and biologics.

Which regulations govern pharma cold chain logistics in 2025? – Learn about GDP, GMP, DSCSA and regional frameworks and what they mean for your operations.

What technologies are transforming cold chain logistics? – Explore IoT sensors, KI-Routenoptimierung, Blockchain, solarpowered storage and automation.

How do you choose packaging and equipment? – Compare insulated containers, Palettenversender, Phasenwechselmaterialien, cryogenic shippers and smart packaging.

How can you build a compliant and resilient cold chain? – Follow our best practice checklist for manufacturing, Lagerung, transport and distribution.

What trends and market developments will shape 2025? – Understand the growth of biologics, sustainability pressures and the push for endtoend visibility【542920472744014†L621-L699】.

What are common cold chain questions? – Find practical answers to FAQs about temperature ranges, Ausflüge, compliance and technology.

Why are Pharma Cold Chain Logistics Best Practices Essential?

Temperature control protects product potency and patient safety. Vaccines and biologic therapies lose effectiveness when exposed to unsuitable temperatures; Zum Beispiel, traditional vaccines must stay between 2 °C und 8 °C, some biologics require –20 °C storage and gene or cell therapies demand –80 °C bis –150 °C cryogenic conditions. Brief excursions can render medicines ineffective. Studies estimate up to 20 % of temperaturesensitive drugs are compromised during transit, costing billions and risking patient health. With the pharmaceutical cold chain market expected to reach UNS $6.6 Milliarden in 2025 Und UNS $9.6 Milliarden von 2035, ensuring reliable cold chain logistics is a competitive necessity.

Financial and reputational stakes are high. Vaccine spoilage wastes almost 50 % of doses worldwide, and cold chain failures can trigger recalls, regulatory penalties and reputational damage. Maintaining a dependable cold chain preserves product integrity, supports compliance and protects your brand.

Die Temperaturanforderungen variieren je nach Produkt. Understanding specific ranges helps you choose appropriate equipment and packaging. The table below summarises common categories:

Temperature Categories and Benefits

Produktkategorie Typischer Temperaturbereich Warum ist es wichtig Praktischer Nutzen
Standardimpfstoffe 2–8 ° C (36–46 ° F.) Die meisten Impfstoffe (flu, hepatitis, HPV) remain potent only within this refrigerated range Ensures immunity and avoids costly revaccination
Biologika & Peptide 2–8 ° C; some require –20 °C Monoklonale Antikörper, insulin and GLP1 agonists degrade quickly outside controlled refrigeration Maintains drug efficacy and reduces patient risks
Gene & Zelltherapien –80 °C bis –150 °C (kryogen) CART therapies and viral vectors require ultracold storage; temperatures can reach –190 °C Preserves living cells and maximises therapeutic success
Kontrollierte Raumtemperatur (CRT) Medikamente 15–25 °C (59–77 °F) Many oral drugs and some biologics can be stored at CRT but need monitoring to avoid heat or freeze damage Avoids product degradation and reduces energy costs
Obesity medications 2–8 ° C GLP1 receptor agonists like Wegovy and Mounjaro require refrigeration Supports growing patient demand and reduces waste

Practical Tips and RealWorld Insights

Always confirm manufacturer ranges. Never assume one range fits all products; verify each drug’s specification.

Use medicalgrade equipment. Purposebuilt refrigerators and freezers deliver uniform temperature; avoid dormitorystyle units that may freeze vaccines.

Türöffnungen minimieren. Frequent door openings introduce warm air and cause fluctuations.

Label storage areas. Clear labels such as “2–8 °C medicines” reduce handling errors.

Record everything. Document every temperature measurement; accurate records support audits and help identify deviations.

Beispiel aus der Praxis: During the COVID19 rollout, clinics using calibrated freezers with IoT sensors maintained ultracold temperatures for mRNA vaccines. Continuous alerts enabled staff to correct deviations quickly, reducing spoilage and ensuring uninterrupted immunisation.

Which Regulations Govern Pharma Cold Chain Logistics in 2025?

Pharmaceutical cold chain logistics operates within a complex regulatory landscape. Failing to comply with guidelines can result in fines, shipment quarantines or license suspensions. Here are the major frameworks you must understand:

Good Distribution and Manufacturing Practice (GDP/GMP)

GDP and GMP guidelines—issued by bodies like the European Medicines Agency (EMA), UNS. Food and Drug Administration (FDA) und Weltgesundheitsorganisation (WER)—set standards for temperature control, traceability and training. Key principles include validated equipment, continuous monitoring and risk management.

Gesetz zur Sicherheit der Arzneimittellieferkette (DSCSA)

In den Vereinigten Staaten, Die DSCSA requires a fully electronic, interoperable tracking system by August 27 2025. Wholesale distributors must exchange transaction information, verify product identifiers at the package level and report suspect medicines. Dispensers must also electronically trace products, with deadlines extending to November 2026 for small dispensers.

Other Regional Frameworks

EU GDP/GMP: Annex 11 mandates validated electronic systems and secure data handling.

USP <1079>: Provides guidelines for shipping temperaturesensitive products.

IATA/WHO: Set standards for transporting vaccines and dry ice.

NIST & UKAS Calibration: Ensures measurement accuracy of monitoring devices.

EU Clinical Trials Regulation (EU 536/2014): Governs investigational products during trials.

Regulierungstabelle

Verordnung Umfang & Hauptanforderungen Implikationen für Sie
DSCSA (UNS) Electronic traceability, serialised product identifiers, full data exchange by Aug 27 2025 Requires interoperable systems and robust data management; noncompliance can halt shipments
EU GDP/GMP Validated electronic systems, secure data handling, audit trails Mandates calibrated equipment, electronic records and user access controls
USP <1079> Guidelines for shipping temperaturesensitive products Supports best practices for packaging, Überwachung und Dokumentation
IATA/WHO Standards for transporting vaccines and dry ice Ensures safe air transport and global consistency
NIST/UKAS Calibration of devices to recognised standards Ensures measurement accuracy for temperature monitoring

Compliance Tips

Review upcoming DSCSA deadlines and assess whether your systems meet interoperability requirements.

Map your operations to identify which regional guidelines apply; adapt processes accordingly.

Create a compliance checklist covering calibration, Überwachung, Dokumentation und Schulung.

Partner with validated vendors. Work with suppliers who provide documentation for audits.

Upgrade electronic systems to maintain secure data, audit trails and user access controls.

Beispiel aus der Praxis: Ein US-Amerikaner. wholesale distributor modernised its warehouse management system to meet DSCSA requirements. By August 2025 it had integrated serialisation, digital documentation and secure user access, avoiding shipment delays and penalties.

Emerging Technologies Transforming Pharma Cold Chain Logistics

Digital tools and hardware are reshaping cold chain logistics in 2025, enhancing visibility, control and efficiency.

IoTEnabled Sensors and RealTime Monitoring

Internet of Things devices—such as smart tapes, sensors and GPS trackers—collect data on temperature, Luftfeuchtigkeit und Standort in Echtzeit. When sensors detect unsafe conditions, they send alerts via text or email, um sofortige Korrekturmaßnahmen zu ermöglichen. IoT sensors with GPS provide endtoend visibility, and predictive analytics can reduce unplanned equipment downtime by up to 50 % and repair costs by 10–20 %.

Künstliche Intelligenz (Ai) and Predictive Analytics

AI algorithms analyse historical and realtime data to optimise shipping routes, Prognostizieren Sie den Bedarf und prognostizieren Sie Geräteausfälle. AIpowered route optimisation considers traffic and weather conditions, Reduzierung der Transitzeit und Qualitätsverluste. Studies indicate AI improves decisionmaking and reduces costs across the cold chain.

Blockchain for EndtoEnd Traceability

Blockchain creates a tamperproof ledger linking every transaction chronologically. In the pharmaceutical cold chain it ensures data integrity, prevents manipulation and enhances compliance. Realtime temperature logs, shipment times and custody data can be shared securely among stakeholders. This transparency builds trust and simplifies audits.

SolarPowered and Sustainable Cold Storage

Unreliable power grids and rising energy costs have spurred solarpowered cold storage units. Solar installations reduce total energy costs—utility rates average 13.10 Cent pro kWh while commercial solar can cost 3.2–15,5 Cent pro kWh. Sustainable packaging such as recyclable containers and biodegradable wraps also reduces environmental impact.

Automatisierung und Robotik

Kühllagereinrichtungen übernehmen automatisierte Lager- und Bereitstellungssysteme (AS/RS) and robotic handling to address labour shortages and improve efficiency. Robots minimise human error and operate without breaks, increasing throughput. Etwa 80 % of warehouses remain unautomated, leaving room for growth.

Portable Cryogenic Freezers and Modular UltraCold Storage

Advanced therapies require ultracold temperatures. Tragbare Kryo-Gefriergeräte halten die Wartung aufrecht –80 °C bis –150 °C conditions and provide realtime tracking and warning notifications. Modular units allow facilities to scale capacity quickly and accommodate multiple temperature zones.

Innovation Summary Table

Technologie Schlüsselvorteile What It Means for You
IoT -Sensoren & GPS Realtime temperature/location data; automatisierte Benachrichtigungen Prevents excursions, optimises routes and enhances visibility
Ai & prädiktive Analytik Forecasts demand, identifies optimal paths Reduces transit time and preserves product quality
Blockchain Tamperproof records, secure data sharing Simplifies audits and strengthens compliance
Solarbetriebener Speicher Lower energy costs, remote operation Enables sustainable cold chain in offgrid areas
Automation/robotics Continuous operation, weniger Fehler Improves warehouse efficiency and labour utilisation
Tragbare kryogene Gefriergeräte Ultracold mobility Supports gene and cell therapies in diverse locations

Implementation Tips

Install IoT sensors on every shipment to monitor temperature and location.

Use AIenabled route planning to adjust deliveries based on realtime traffic and weather.

Adopt blockchain logs for highvalue or highly regulated products.

Evaluate solar options if your facility faces unreliable power or high energy costs.

Plan for automation to cope with labour shortages and ensure consistency.

Beispiel aus der Praxis: A Southeast Asian logistics provider deployed blockchain and IoT sensors to monitor vaccine shipments. By sharing realtime temperature and humidity logs with all stakeholders, the system eliminated data manipulation and improved regulatory compliance.

Selecting Packaging and Equipment for Pharma Cold Chain Logistics

Effective cold chain management requires more than refrigerators. Packaging and equipment must preserve product integrity during manufacturing, storage and transport. Isolierte Behälter, Palettenversender, phasechange materials and cryogenic units each offer unique benefits.

Verpackungsoptionen

Insulated containers and liners: Represent about 40 % of the cold chain packaging market. They maintain temperature stability for 96 hours or more and can be reusable.

Palettenversender: Designed for largevolume shipments, they account for roughly 25 % of the market and can integrate smart sensors.

Phasenwechselmaterialien (PCMs) und Gelpackungen: Provide precise temperature control by absorbing or releasing latent heat; custom PCMs exist for frozen (–20 °C), gekühlt (+5 °C) und Ambiente (+22 °C) conditions【542920472744014†L511-L448】.

Vakuumisolationsgremien (VIPs): Offer superior insulation and thermal stability and can be custom shaped.

Cryogenic shippers and LN2 vapour shippers: Pflegen –80 °C to –190 °C for gene and cell therapies.

Smart packaging platforms: Combine AI and IoT to recommend packaging and track temperature in real time.

Reusable vs SingleUse Packaging

Reusable systems reduce total cost of ownership and environmental impact; the market for reusable temperaturecontrolled packaging reached UNS $2.5 Milliarden in 2024 and is expected to double by 2033. Singleuse options may be necessary for regulatory reasons or when return logistics are impractical. Bei der Auswahl der Verpackung, consider route duration, seasonal temperatures and sustainability goals.

Equipment Considerations

Medicalgrade refrigerators/freezers: Provide uniform temperature and microprocessor controls with alarms.

Ultralow freezers: Required for biologics and gene therapies; ensure redundancy and backup power.

IoTenabled shippers and data loggers: Offer continuous temperature and location data; calibrate regularly.

Backup generators and redundant power: Ensure temperature stability during outages.

Packaging Selection Table

Lösung Temperature Range Supported Use Cases Vorteile
Isolierte Behälter (EVP, VIP) 2–8 ° C, –20 °C, –80 °C (with appropriate refrigerants) Impfstofflieferungen, Biologika, Insulin Leicht, wiederverwendbar, Sondergrößen; maintain temperature for 96 h oder mehr
Palettenversender 2–8 ° C, –20 °C, cryogenic with dry ice Largevolume distribution, international transport Lange Haltezeiten; dauerhaft; can integrate smart sensors
PCM & Gelpackungen Specific ranges (–20 °C, +5 °C, +22 °C) Gemischte Sendungen, klinische Studien Präzise Temperaturregelung; wiederverwendbar; safe for dry ice restrictions
Cryogenic freezers & LN2 vapour shippers –80 °C to –190 °C Cell and gene therapy, tissue engineering Maintain viability of living cells; require specialised handling
Intelligente Verpackungen All ranges; dynamic Highvalue biologics, Fernlieferungen Data integration, Routenoptimierung; reduces packaging errors

UserLevel Tips

Conduct thermal validation of packaging for specific routes and conditions.

Kältemittel vorkonditionieren (Gelpackungen, PCMs) to the correct temperature before packing.

Avoid midroute repacking; each opening introduces risk.

Use data loggers and GPS trackers to document temperature throughout transit.

Consider reusable systems for regular routes to reduce costs and waste.

Beispiel aus der Praxis: A biotech firm shipping a gene therapy used cryogenic LN₂ vapour shippers with IoT sensors. These containers maintained –150 °C für über 120 Std. and provided realtime data, enabling proactive interventions and avoiding product loss.

Building a Compliant and Resilient Pharma Cold Chain System

A robust cold chain extends beyond equipment; it relies on processes, people and risk management. The table below summarises core components across the pharmaceutical cold chain.

Core Components Across the Cold Chain

Bühne Schlüsselaktivitäten Typischer Temperaturbereich Praktische Implikationen
Herstellung Maintain specified temperatures for raw materials and finished products; document them for tech transfer 2–8 °C for most biologics; –20 °C or lower for gene therapies Ensures ingredients remain stable and prevents degradation before packaging
Lagerung Use refrigerators, cold rooms and warehouses with continuous monitoring and alarms 2–8 ° C (gekühlt) or lower for ultracold products Protects inventory; temperature logs support audits and recalls
Transport Employ refrigerated vehicles and insulated packaging; data loggers track conditions in transit Usually 2–8 °C; dry ice or liquid nitrogen for cryogenic transport Minimises risk during delivery; documents chain of custody
Verteilung Wholesalers and pharmacies use controlled facilities until dispensing Same as storage Ensures final product quality and prevents waste

Best Practice Checklist

Validieren Sie die Ausrüstung: Confirm refrigerators, freezers and data loggers meet GMP/GDP standards and calibrate them regularly.

Implement continuous monitoring: Use IoT devices and alarm systems to track temperature and humidity in real time.

Sorgen Sie für eine solide Dokumentation: Temperaturdaten aufzeichnen, calibration certificates and handling procedures; consider blockchain for tamperproof records.

Personal schulen: Provide comprehensive training on GDP requirements, equipment operation and emergency response.

Entwickeln Sie Notfallpläne: Prepare backup power sources, alternative routes and protocols for transferring products to secondary storage.

Conduct risk assessments: Identify potential failures (Stromausfälle, vehicle breakdowns, extreme weather) and mitigate them with redundancy and predictive tools.

Auditieren Sie regelmäßig: Include internal and external audits to verify compliance and uncover gaps.

Interactive SelfAssessment Tool

Engage your team by adding a Cold Chain Readiness Quiz. Ask questions like:

Do you know the correct storage temperature for each product?

Are your refrigerators and freezers calibrated within the last year?

Do you use realtime monitoring with alerts?

Do you have documented SOPs for packing and handling?

Is there a contingency plan for power failures or transit delays?

A scoring system can highlight weak areas and direct users to resources or services for improvement. Zum Beispiel, a regional pharmacy chain implemented a quarterly selfassessment and achieved a 30 % Reduzierung der Temperaturschwankungen innerhalb von sechs Monaten.

2025 Developments and Trends in Pharma Cold Chain Logistics

The pharmaceutical cold chain is evolving rapidly due to new therapies, rising consumer expectations and sustainability mandates.

Trendübersicht

Automatisierung und Robotik: Cold storage facilities deploy robots to address labour shortages and improve consistency.

Nachhaltigkeit: Energieeffiziente Kühlung, renewable energy and recyclable packaging are becoming industry standards. Sustainable practices help reduce carbon footprints—cold chain infrastructure accounts for around 2 % der weltweiten CO₂-Emissionen.

End-to-End-Sichtbarkeit: Advanced tracking systems provide realtime location and temperature data. The hardware segment led the cold chain tracking and monitoring market in 2022, festhalten 76.4 % des Marktanteils.

Infrastructure modernisation: Upgrades in insulation, refrigeration systems and onsite renewable power are essential to meet efficiency and compliance demands.

KI und Predictive Analytics: AI optimises routes, forecasts demand and predicts equipment failures; demand forecasting addresses uncertainty in supply chains.

Growth in pharma cold chain: The rising demand for temperaturesensitive pharmaceuticals and biologics is a key driver. Etwa 20 % of new drugs in development are gene and cellbased therapies requiring cold chain logistics. The global pharmaceutical cold chain market is expected to reach UNS $1,454 Milliarden von 2029, mit einer CAGR von 4.71 % aus 2024 Zu 2029.

Sustainability and green supply chains: Sustainability tops the list at major industry events, with ecofriendly materials and renewable energy emphasised. Cold chain operators invest in energyefficient refrigeration and ecofriendly refrigerants.

Endtoend visibility as standard: Full visibility is now required across product recalls, Einhaltung, cold chain integrity and raw material sourcing.

Resilience and risk management: PostCOVID19, supply networks focus on resilience and nearshoring to reduce disruptions. Simulation tools and scenario planning help prepare for unpredictable events.

Neueste Fortschrittshighlights

Rise of biologics and advanced therapies: Über 40 % of newly approved drugs in 2024 were biologics, driving demand for refrigerated and cryogenic storage.

Refrigerated storage growth: Demand for 2–8 °C storage is growing faster than other segments; biologics are projected to grow 6 % CAGR durch 2035 und Impfstoffe 5 % CAGR. Obesity medications are expected to triple in volume by 2030.

Cold storage market expansion: The global cold storage market (food and pharmaceuticals) wird voraussichtlich wachsen UNS $35.7 Milliarden in 2025 Zu UNS $72 Milliarden von 2033.

Modernisation of warehouses: Um 80 % of warehouses remain unautomated, offering significant potential for robotics and automation.

High growth for cold chain logistics: The global cold chain logistics market is predicted to grow from UNS $324.85 Milliarden in 2024 Zu UNS $862.33 Milliarden von 2032 due to demand for biologics and stricter regulations.

Standardisation and integration: Von 2025, 74 % of logistics data is expected to be standardized, enabling better integration across supply chains.

Market Insights and Future Outlook

Therapies are becoming more sophisticated, making temperaturecontrolled logistics a strategic asset. Biologics and personalised medicines are highly sensitive to temperature and frequently require refrigerated storage. Vaccines and rare disease treatments also rely on the 2–8 °C range. Obesity treatments using GLP1 agonists are fuelling explosive growth in refrigerated volumes. In der Zwischenzeit, environmental and ESG pressures push companies to adopt energyefficient refrigeration, renewable power and biodegradable packaging. Strategic partnerships and data standardisation enable better integration across supply chains, improving resilience.

Häufig gestellte Fragen

Q1: What does pharmaceutical cold chain logistics mean?
It refers to controlling temperature during manufacturing, Lagerung, transport and distribution of temperaturesensitive medicines. The goal is to keep products like vaccines, biologics and gene therapies within specific ranges (Z.B., 2–8 ° C) to maintain potency and safety.

Q2: How are temperature ranges categorised in the cold chain?
The Healthcare Distribution Alliance classifies four ranges: gekühlt (2–8 ° C) for insulin and many vaccines; gefroren (–20 °C bis –40 °C) for DNA and mRNA vaccines; ultralow (–45 °C to –93 °C) for certain vaccines; und kryogen (–150 °C to –190 °C) for cell and gene therapies. Knowing these categories helps you select suitable equipment and packaging.

Q3: What happens if temperature excursions occur?
Temperature excursions—when products fall outside recommended ranges—are the leading cause of product loss. Bis zu 80 % of pharmaceutical losses are attributed to temperature excursions. Excursions degrade drug potency, trigger costly recalls and compromise patient safety. Implement continuous monitoring and contingency plans to mitigate risks.

Q4: How can pharmacies ensure compliance with GDP guidelines?
Pharmacies should use validated equipment, continuous monitoring with realtime alerts, robust documentation and regular staff training. They must maintain products within 2–8 °C or other specified ranges, conduct risk assessments and develop contingency plans for power outages or transit delays.

Q5: What new technologies are emerging in 2025 Für Kaltkettenlogistik?
Key innovations include IoT sensors for realtime monitoring, KI-gesteuerte Routenoptimierung, blockchain for tamperproof recordkeeping, Solarbetriebener Kühlraum, automation and robotics. Portable cryogenic units and modular ultracold storage support gene and cell therapies.

Q6: Why is sustainability important in pharmaceutical cold chains?
Cold storage facilities consume large amounts of energy and contribute to carbon emissions. Sustainable practices—such as using renewable energy, energyefficient refrigeration and recyclable packaging—reduce environmental impact and help companies meet regulatory and consumer expectations. Solarpowered units can also lower operational costs.

Q7: How will the pharmaceutical cold chain evolve over the next decade?
The next ten years will see rapid growth in 2–8 °C storage, automation and realtime visibility. Biologics are projected to grow 6 % CAGR durch 2035; Impfungen 5 %, and obesity medications will triple by 2030. Ultracold logistics will expand to support cell and gene therapies, while sustainable and modular solutions will become standard.

Zusammenfassung und Empfehlungen

Key Takeaways:

Keep temperatures correct. Understand the specific range for each product and use validated, calibrated equipment to maintain it. Most vaccines and biologics require 2–8 °C, while gene and cell therapies need –80 °C to –150 °C.

Befolgen Sie die Vorschriften. Adhere to GDP/GMP guidelines, prepare for DSCSA electronic traceability by Aug 27 2025, and comply with regional standards.

Embrace technology. IoT -Sensoren, AI analytics and blockchain improve visibility, optimise routes and ensure tamperproof records.

Wählen Sie eine geeignete Verpackung. Verwenden Sie isolierte Behälter, Palettenversender, PCMs or cryogenic units based on temperature requirements and route duration.

Train and plan. Educate staff on cold chain protocols, maintain detailed documentation and develop contingency plans for emergencies.

Priorisieren Sie Nachhaltigkeit. Invest in energyefficient refrigeration, renewable power and recyclable packaging.

Action Recommendations:

Bewerten Sie Ihre Kühlkettenbereitschaft. Conduct a selfassessment to identify gaps in equipment, Überwachung, Dokumentation und Schulung. Score results to prioritise improvements.

Upgrade monitoring infrastructure. Implement IoT sensors and AIenabled analytics to achieve realtime visibility and predictive insights.

Create a DSCSA compliance roadmap. Plan for electronic traceability, serialisation and secure user access by August 27 2025.

Optimise packaging and transport. Choose reusable insulated containers or cryogenic shippers as needed; validate thermal performance for your routes.

Investieren Sie in Nachhaltigkeit. Explore solarpowered storage, energyefficient refrigeration and recyclable packaging to reduce costs and environmental impact.

Arbeiten Sie mit Experten zusammen. Partner with 3PL/4PL providers and packaging specialists who understand pharmaceutical regulations and offer endtoend visibility.

Über Tempk

Bei Tempk, we specialise in cold chain packaging and temperature control solutions for pharmaceuticals. With an inhouse R&D centre and stringent quality control, we design and manufacture insulated boxes, Gelpackungen, pallet covers and reusable packaging tailored for 0–10 °C, sub10 °C and ultracold ranges. Our validated systems help clients comply with GDP/GMP requirements while reducing waste and supporting sustainability goals. We prioritise ecofriendly materials and innovative designs to keep your shipments safe and efficient in 2025.

Aufruf zum Handeln: Ready to strengthen your pharma cold chain? Contact Tempk for customised solutions and expert guidance on building a resilient, sustainable cold chain system.

Vorherige: Wachstum der Pharma-Kühlkettenlogistik 2025: Trends & Strategien Nächste: Pharma Cold Chain Logistics Training: Mastering GDP & Technology in 2025